IRWD (Ironwood Pharma) Company Value to Revenue

Public company logo of Ironwood Pharmaceuticals (IRWD)

Ironwood Pharmaceuticals (IRWD) is scaling Linzess sales and expanding its GI portfolio, while the EV/Sales ratio on GURU.Markets reflects valuation dynamics where the 2572.00 mark indicates the business valuation level. Market capitalization is supported by demand from millions of patients with chronic intestinal pathologies. The stable US legal framework and the humanitarian status of the industry guarantee the company complete geopolitical neutrality.

Ironwood Pharmaceuticals Inc (IRWD): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

Financial and market metric breakdowns for Ironwood Pharmaceuticals, Inc. (IRWD)

- share price and consensus valuation forecast:
- business market valuation indicators:
- money and cash flow information:
Initial company analysis:Ironwood Pharma
Finished products of ironwoodpharma.com

This indicator reflects the enterprise value, accounting for net debt, relative to sales volume. By analyzing the change in the company's value-to-revenue ratio, an investor determines the capitalization efficiency of every dollar of income. The metric is sensitive to debt load and operating margins. For Ironwood Pharmaceuticals (IRWD), this balance depends on the costs of implementing "green chemistry" environmental standards. Reducing production toxicity impacts the long-term valuation of assets.